p28 Peptide - CDG Therapeutics

Drug Profile

p28 Peptide - CDG Therapeutics

Alternative Names: Azurin-derived cell-penetrating peptide p28; Azurin-p28; Cell penetrating peptide; NSC-745104

Latest Information Update: 04 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator CDG Therapeutics
  • Developer CDG Therapeutics; Pediatric Brain Tumor Consortium; University of Illinois at Chicago
  • Class Antineoplastics; Peptides
  • Mechanism of Action Tumour suppressor protein p53 modulators; Ubiquitin-protein ligase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I CNS cancer
  • No development reported HIV infections; Solid tumours

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Solid-tumours(Second-line therapy or greater, In adults) in USA (IV, Infusion)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in HIV-infections in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top